Bracco announces FDA approval of gadopiclenol injection, a new macrocyclic high-relaxivity gadolinium-based contrast agent which will be commercialised as Vueway

Bracco Diagnostics

21 September 2022 - Vueway injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use.

Bracco Diagnostics announced today that the US FDA has approved gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent, which shows the highest relaxivity compared to all the other gadolinium-based contrast agents available today in the United States.

Read Bracco Diagnostics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Diagnostic agent